PROM1 and myocardial infarction: In November 2011, CAT/EMA agencies published a scientific recommendation concerning the classification of autologous BM-MNCs and autologous BM-derived CD133+ cells intended for the treatment of postacute myocardial infarction and chronic ischemic heart disease as ATMPs [31].